HCII HPV TEST (DIGENE HPV TEST USING HYBRID CAPTURE II TECHNOLOGY)

Kit, Dna Detection, Human Papillomavirus

FDA Premarket Approval P890064 S006

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for chaning the solid phase on which the rna:dna hybrids are captured from polystyrene tubes to a 96-well microtiter place addition of a new cervical specimen collection kit (digene cervical sampler), addition of the digene sample conversion kit,a nd the addition of new assay performance characteristics. The device, as modified, will be marketed under the trade name digene hpv test using hybrid capture(r) ii technology (hcii hpv) witht he following indications: the digene hpv test using hybrid capture ii technology is a nucleic acid signal enhanced solution hybridization microplate assay using chemiluminescence for the qualitative detection of eighteen types of human papillomavirus (hpv) dna in cervical specimens. The digene hpv test can differentiate between two hpv dna groups: low risk hpv types 6/11/42/43/44; and high/intermediate risk hpv types 16/18/31/33/35/39/45/51/52/56/58/59/68, but cannot determine the specific hpv type present. Cervical specimens which may be tested with the digene hpv test include the following: 1) specimens collected with the digene cervical sampler; 2) biopsies collected in the digene specimen transport medium; 3) specimens collected using a broom-type collection device and placed in cytye preservcyt solution (refer to the digen sample converstion kit package insert for complete details).

DeviceHCII HPV TEST (DIGENE HPV TEST USING HYBRID CAPTURE II TECHNOLOGY)
Classification NameKit, Dna Detection, Human Papillomavirus
Generic NameKit, Dna Detection, Human Papillomavirus
ApplicantQIAGEN GAITHERSBURG, INC
Date Received1997-09-30
Decision Date1999-03-17
PMAP890064
SupplementS006
Product CodeMAQ
Advisory CommitteeMicrobiology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address QIAGEN GAITHERSBURG, INC 1900 Germantown Road germantown, MD 20874

Supplemental Filings

Supplement NumberDateSupplement Type
P890064Original Filing
S041 2020-05-20 30-day Notice
S040 2018-02-28 30-day Notice
S039 2018-02-16 30-day Notice
S038 2018-02-16 30-day Notice
S037 2018-01-26 30-day Notice
S036 2018-01-11 30-day Notice
S035 2017-11-30 30-day Notice
S034 2017-06-29 30-day Notice
S033 2016-02-19 Real-time Process
S032 2015-04-28 Normal 180 Day Track No User Fee
S031 2014-09-23 Real-time Process
S030 2014-03-21 Real-time Process
S029 2013-08-15 Normal 180 Day Track No User Fee
S028
S027 2011-07-28 Normal 180 Day Track No User Fee
S026 2011-02-28 Real-time Process
S025 2011-02-28 30-day Notice
S024 2010-04-15 30-day Notice
S023 2010-04-15 30-day Notice
S022 2010-04-15 30-day Notice
S021 2010-02-03 Normal 180 Day Track No User Fee
S020 2008-01-29 Normal 180 Day Track No User Fee
S019
S018 2006-03-24 Real-time Process
S017 2004-11-19 Special (immediate Track)
S016
S015 2004-05-28 Real-time Process
S014 2003-11-05 Normal 180 Day Track
S013 2003-10-01 Real-time Process
S012 2003-05-20 Special (immediate Track)
S011
S010
S009 2001-10-01 Panel Track
S008 2000-08-25 Normal 180 Day Track
S007 2000-02-07 Normal 180 Day Track
S006 1997-09-30 Normal 180 Day Track
S005 1996-11-01 Normal 180 Day Track
S004 1996-05-03 Normal 180 Day Track
S003 1993-09-27 Normal 180 Day Track
S002 1992-12-09 Normal 180 Day Track
S001 1991-10-18 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
04053228010777 P890064 000
04053228002031 P890064 000
04053228002024 P890064 000
04053228002000 P890064 000
14053228002014 P890064 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.